group_name,group_level,strata_name,strata_level,window_name,variable,variable_type,variable_level,estimate_type,estimate,cdm_name,generated_by
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,denominator,binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,66,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,91,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,64,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,82,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,denominator,binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,49,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,denominator,binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,denominator,binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,denominator,binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,denominator,binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,denominator,binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,denominator,binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,denominator,binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ADRENERGICS FOR SYSTEMIC USE (21603302),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,denominator,binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: EMOLLIENTS AND PROTECTIVES (21601969),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,denominator,binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,denominator,binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,denominator,binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION (21604015),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS (21602143)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIFUNGALS FOR SYSTEMIC USE (21601964),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: POSTERIOR PITUITARY LOBE HORMONES (21602697),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: VITAMIN K AND OTHER HEMOSTATICS (21601043),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIFIBRINOLYTICS (21601033),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ENZYMES (21601997),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-365 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-365 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-365 to -1,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-365 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-365 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-365 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-365 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,denominator,binary,NA,count,170,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,48,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,denominator,binary,NA,count,124,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,denominator,binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,denominator,binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,denominator,binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,denominator,binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,-30 to -1,denominator,binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,denominator,binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,denominator,binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,denominator,binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,denominator,binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,denominator,binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,denominator,binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OPIOIDS (21604254),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,-30 to -1,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,-30 to -1,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,-30 to -1,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,-30 to -1,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,-30 to -1,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,-30 to -1,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,denominator,binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,169,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,38,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,denominator,binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,123,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,denominator,binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,denominator,binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,denominator,binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,denominator,binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,57,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,denominator,binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,denominator,binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,denominator,binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,denominator,binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,denominator,binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,denominator,binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,0 to 0,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,0 to 0,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,0 to 0,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,0 to 0,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,0 to 0,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,0 to 0,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,0 to 0,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,0 to 0,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,denominator,binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,62,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,50,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,denominator,binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,34,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,denominator,binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,denominator,binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,denominator,binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,31,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,denominator,binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,denominator,binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,denominator,binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,denominator,binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,denominator,binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,denominator,binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,denominator,binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CALCIUM (21600858),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OPIOIDS (21604254),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: POTASSIUM (21600875),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 30,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 30,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 30,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 30,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 30,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 30,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 30,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,denominator,binary,NA,count,167,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,56,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,35,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,80,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,171,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,92,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,63,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,41,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,69,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,79,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,denominator,binary,NA,count,122,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,47,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Overall,Overall,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Overall,Overall,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,43,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,45,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,25,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,denominator,binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,denominator,binary,NA,count,73,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,33,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,61,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,denominator,binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,44,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,40,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,denominator,binary,NA,count,46,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,denominator,binary,NA,count,55,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,26,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: IMMUNOSTIMULANTS (21603849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,denominator,binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,23,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,denominator,binary,NA,count,58,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: INTESTINAL ANTIINFECTIVES (21600601),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,denominator,binary,NA,count,39,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PARATHYROID HORMONES AND ANALOGUES (21602780),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, EXCL. THIAZIDES (21601489)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER DIURETICS (21601556),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: MYDRIATICS AND CYCLOPLEGICS (21605058),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,denominator,binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,20,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM (21602618),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DECONGESTANTS AND ANTIALLERGICS (21605071),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: MEDICATED DRESSINGS (21602262),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,17,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIFUNGALS FOR TOPICAL USE (21601909),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,denominator,binary,NA,count,87,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: TUMOUR DETECTION (21605536),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,denominator,binary,NA,count,54,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,27,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BETA BLOCKING AGENTS AND THIAZIDES (21601701),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: IMMUNOGLOBULINS (21601254),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: POTASSIUM-SPARING AGENTS (21601532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: I.V. SOLUTIONS (21601153),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIVARICOSE THERAPY (21601634),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ESTROGENS (21602514),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: PERIPHERAL VASODILATORS (21601561),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BETA-LACTAM ANTIBACTERIALS, PENICILLINS (21602818)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER GYNECOLOGICALS (21602452),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTINEMATODAL AGENTS (21604939),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CARDIAC GLYCOSIDES (21601239),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS (21602361)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING (21600409)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,29,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,36,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DIRECT ACTING ANTIVIRALS (21603127),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CORTICOSTEROIDS (21605199),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER NUTRIENTS (21605348),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CONTRACEPTIVES FOR TOPICAL USE (21602445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: CHEMOTHERAPEUTICS FOR TOPICAL USE (21602073),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: DIGESTIVES, INCL. ENZYMES (21600698)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS (21602158)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTACIDS (21600047),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION (21601541),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: LOCAL ANESTHETICS (21605096),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,18,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS (21604070)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER HEMATOLOGICAL AGENTS (21601226),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: OTHER ANTINEOPLASTIC AGENTS (21603746),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTI-DEMENTIA DRUGS (21604792),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTISEPTICS AND DISINFECTANTS (21602196),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIMETABOLITES (21601421),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS (21600128),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS (21600201),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,denominator,binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ACE INHIBITORS, COMBINATIONS (21601801)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTITHYROID PREPARATIONS (21602759),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIDIARRHEAL MICROORGANISMS (21600667),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS (21603366)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ULTRASOUND CONTRAST MEDIA (21605437),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIADRENERGIC AGENTS, CENTRALLY ACTING (21600382)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: NASAL DECONGESTANTS FOR SYSTEMIC USE (21603207),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: QUINOLONE ANTIBACTERIALS (21603006),binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,32,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIINFECTIVES (21603552),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIBIOTICS FOR TOPICAL USE (21602055),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANESTHETICS, GENERAL (21604182)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ALL OTHER THERAPEUTIC PRODUCTS (21605228),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: MULTIVITAMINS, COMBINATIONS (21600801)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,16,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: OTHER OPHTHALMOLOGICALS (21605125),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: X-RAY CONTRAST MEDIA, IODINATED (21605373)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIPSORIATICS FOR TOPICAL USE (21602029),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,52,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE (21602318),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,42,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,15,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS (21601765),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: SULFONAMIDES AND TRIMETHOPRIM (21602929),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,19,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM (21604171),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIPSYCHOTICS (21604490),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES (21604849),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANXIOLYTICS (21604564),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: UROLOGICALS (21602628),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER BETA-LACTAM ANTIBACTERIALS (21602868),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,denominator,binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: IRRIGATING SOLUTIONS (21601167),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OPIOIDS (21604254),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIDEPRESSANTS (21604686),binary,NA,count,24,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,13,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,30,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HORMONES AND RELATED AGENTS (21603813),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS (21603395)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER MINERAL SUPPLEMENTS (21600884),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (21605418),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: VASODILATORS USED IN CARDIAC DISEASES (21600315),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: STOMATOLOGICAL PREPARATIONS (21600003),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (21604147),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: ANTIINFECTIVES (21605145),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: CORTICOSTEROIDS, OTHER COMBINATIONS (21602178)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,37,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTITHROMBOTIC AGENTS (21600961),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: THYROID PREPARATIONS (21602752),binary,NA,count,22,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: THROAT PREPARATIONS (21603216),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS (21603436)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DRUGS FOR TREATMENT OF TUBERCULOSIS (21603090),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,sle,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: BELLADONNA AND DERIVATIVES, PLAIN (21600190)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS USED IN ADDICTIVE DISORDERS (21604816),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: DOPAMINERGIC AGENTS (21604462),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: ANESTHETICS, LOCAL (21604220)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIPROPULSIVES (21600642),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: HYPNOTICS AND SEDATIVES (21604606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIHISTAMINES FOR SYSTEMIC USE (21603445),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BACTERIAL VACCINES (21601279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS (21602968)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS (21603282)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS (21601745),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIMYCOTICS FOR SYSTEMIC USE (21603072),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS (21601445),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS (21601832)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR CONSTIPATION (21600532),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: HIGH-CEILING DIURETICS (21601516),binary,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS (21603933)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: BILE THERAPY (21600510),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: POTASSIUM (21600875),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: INSULINS AND ANALOGUES (21600713),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO (21600810)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: OTHER CARDIAC PREPARATIONS (21600360),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: PROPULSIVES (21600482),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: OTHER ANTIBACTERIALS (21603041),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: ANTIEPILEPTICS (21604390),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: OTHER ANTIDIARRHEALS (21600672),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIMIGRAINE PREPARATIONS (21604364),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,12,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: HORMONE ANTAGONISTS AND RELATED AGENTS (21603829),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY (21602666),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: CALCIUM CHANNEL BLOCKERS AND DIURETICS (21601779),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN (21602723)",binary,NA,count,14,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE (21605009),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ADRENERGICS, INHALANTS (21603249)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: AMINOGLYCOSIDE ANTIBACTERIALS (21602990),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS (21600744)",binary,NA,count,8,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,21,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. (21602003)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER NERVOUS SYSTEM DRUGS (21604838),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,9,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANDROGENS (21602506),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION (21603650),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,covid,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES (21603327),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: OTHER ANALGESICS AND ANTIPYRETICS (21604303),binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,ATC 3rd: CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION (21605204),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: CALCIUM (21600858),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON (21600424)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: PROGESTOGENS (21602537),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE (21601606),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) (21600080),binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,sle,1 to 365,"ATC 3rd: LOW-CEILING DIURETICS, THIAZIDES (21601462)",binary,NA,count,4,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIMALARIALS (21604886),binary,NA,count,88,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES (21600279),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: OTHER DERMATOLOGICAL PREPARATIONS (21602324),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIGOUT PREPARATIONS (21604129),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,"ATC 3rd: LIPID MODIFYING AGENTS, PLAIN (21601854)",binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTICHOLINERGIC AGENTS (21604444),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: IRON PREPARATIONS (21601078),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: TETRACYCLINES (21602797),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE (21602472),binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: OTHER DIAGNOSTIC AGENTS (21605297),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: BETA BLOCKING AGENTS (21601665),binary,NA,count,11,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: ANTIEMETICS AND ANTINAUSEANTS (21600491),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,ATC 3rd: VITAMIN B12 AND FOLIC ACID (21601119),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS (21604752)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN (21604035),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTIGLAUCOMA PREPARATIONS AND MIOTICS (21603671),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: ANTI-ACNE PREPARATIONS FOR TOPICAL USE (21602282),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: ANTIARRHYTHMICS, CLASS I AND III (21600248)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,multiple,1 to 365,"ATC 3rd: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 (21600823)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,"ATC 3rd: BACTERIAL AND VIRAL VACCINES, COMBINED (21601370)",binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN (21601822)",binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,"ATC 3rd: ACE INHIBITORS, PLAIN (21601783)",binary,NA,count,10,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: I.V. SOLUTION ADDITIVES (21601194),binary,NA,count,3,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,none,1 to 365,ATC 3rd: INTESTINAL ANTIINFLAMMATORY AGENTS (21600651),binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: IMMUNOSUPPRESSANTS (21603891),binary,NA,count,60,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS (21604091)",binary,NA,count,6,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: ANTIINFECTIVES (21605188),binary,NA,count,2,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,"ATC 3rd: CORTICOSTEROIDS, PLAIN (21602099)",binary,NA,count,5,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PROGESTOGENS AND ESTROGENS IN COMBINATION (21602566),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,none,1 to 365,ATC 3rd: VIRAL VACCINES (21601329),binary,NA,count,28,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_hydroxychloroquine,Indication,multiple,1 to 365,ATC 3rd: ANTIINFLAMMATORY AGENTS (21603616),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,1 to 365,ATC 3rd: PARASYMPATHOMIMETICS (21604802),binary,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.0_summariseCharacteristicsFromCodelist
